Surface Oncology, Inc. – NASDAQ:SURF
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Surface Oncology stock price monthly change
+8.56%
month
Surface Oncology stock price quarterly change
+32.89%
quarter
Surface Oncology stock price yearly change
-18.94%
year
Surface Oncology key metrics
Market Cap | 65.08M |
Enterprise value | 16.64M |
P/E | -0.57 |
EV/Sales | 0.27 |
EV/EBITDA | -0.27 |
Price/Sales | 0.61 |
Price/Book | 0.39 |
PEG ratio | -0.01 |
EPS | -1.54 |
Revenue | N/A |
EBITDA | -81.60M |
Income | -94.00M |
Revenue Q/Q | N/A |
Revenue Y/Y | -1.78% |
Profit margin | -105.98% |
Oper. margin | -103.11% |
Gross margin | 0% |
EBIT margin | -103.11% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSurface Oncology stock price history
Surface Oncology stock forecast
Surface Oncology financial statements
| Sep 2022 | 0 | -23.58M | |
|---|---|---|---|
| Dec 2022 | 30M | -21.48M | -71.61% |
| Mar 2023 | 0 | -20.75M | |
| Jun 2023 | 0 | -28.19M |
| Sep 2022 | 181621000 | 68.80M | 37.88% |
|---|---|---|---|
| Dec 2022 | 159910000 | 66.50M | 41.59% |
| Mar 2023 | 137008000 | 61.17M | 44.65% |
| Jun 2023 | 66006000 | 16.82M | 25.49% |
| Sep 2022 | -18.82M | 323K | 8.77M |
|---|---|---|---|
| Dec 2022 | -21.75M | 7.52M | 43K |
| Mar 2023 | -23.43M | 1.43M | 77K |
| Jun 2023 | -19.56M | 32.07M | -28.24M |
Surface Oncology alternative data
| Aug 2023 | 60 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 35 |
| Jun 2024 | 35 |
| Jul 2024 | 35 |
Surface Oncology other data
30.23%
-18.13%
of SURF is owned by hedge funds
54
-23
16.85M
-11.70M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 37090 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | FEES JESSICA officer: Chief Financial Officer | Common Stock | 9,434 | $0.94 | $8,868 | ||
Sale | ONEILL ALISON officer: Chief Medical Officer | Common Stock | 7,042 | $0.94 | $6,619 | ||
Sale | ROSS ROBERT W. officer: Chief Ex.. | Common Stock | 16,713 | $0.94 | $15,710 | ||
Sale | ADAMS CHANDRA officer: Deputy GC | Common Stock | 3,901 | $0.94 | $3,667 | ||
Sale | PALOMBELLA VITO J. officer: Chief Sc.. | Common Stock | 4,463 | $1.72 | $7,676 | ||
Sale | FEES JESSICA officer: Chief Financial Officer | Common Stock | 5,980 | $1.72 | $10,286 | ||
Sale | ROSS ROBERT W. officer: Chief Ex.. | Common Stock | 10,594 | $1.72 | $18,222 | ||
Sale | ONEILL ALISON officer: Chief Medical Officer | Common Stock | 4,463 | $1.72 | $7,676 | ||
Sale | RATH HENRY C. officer: Chief Business Officer | Common Stock | 5,676 | $1.72 | $9,763 | ||
Sale | ONEILL ALISON officer: Chief Medical Officer | Common Stock | 14,809 | $6.1 | $90,335 |
| Patent |
|---|
Application Filling date: 25 Sep 2019 Issue date: 18 Aug 2022 |
Application Filling date: 19 Nov 2021 Issue date: 26 May 2022 |
Grant Filling date: 22 Mar 2019 Issue date: 17 May 2022 |
Grant Filling date: 21 Jun 2018 Issue date: 26 Apr 2022 |
Grant Utility: Anti-CD112R compositions and methods Filling date: 19 Jul 2019 Issue date: 22 Mar 2022 |
Grant Utility: Anti-CD112R compositions and methods Filling date: 19 Jul 2019 Issue date: 4 Jan 2022 |
Application Filling date: 13 Mar 2019 Issue date: 25 Nov 2021 |
Application Filling date: 19 Jul 2019 Issue date: 19 Aug 2021 |
Application Filling date: 30 May 2019 Issue date: 15 Jul 2021 |
Application Filling date: 25 Sep 2020 Issue date: 22 Apr 2021 |
| Insider | Compensation |
|---|---|
| Dr. Robert W. Ross M.D. (1974) Pres, Chief Executive Officer & Director | $705,900 |
| Dr. Vito J. Palombella (1963) Chief Scientific Officer | $672,510 |
-
When is Surface Oncology's next earnings date?
Unfortunately, Surface Oncology's (SURF) next earnings date is currently unknown.
-
Does Surface Oncology pay dividends?
No, Surface Oncology does not pay dividends.
-
How much money does Surface Oncology make?
Surface Oncology has a market capitalization of 65.08M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1016.49% to 30M US dollars.
-
What is Surface Oncology's stock symbol?
Surface Oncology, Inc. is traded on the NASDAQ under the ticker symbol "SURF".
-
What is Surface Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Surface Oncology?
Shares of Surface Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Surface Oncology's key executives?
Surface Oncology's management team includes the following people:
- Dr. Robert W. Ross M.D. Pres, Chief Executive Officer & Director(age: 51, pay: $705,900)
- Dr. Vito J. Palombella Chief Scientific Officer(age: 62, pay: $672,510)
-
How many employees does Surface Oncology have?
As Jul 2024, Surface Oncology employs 35 workers.
-
When Surface Oncology went public?
Surface Oncology, Inc. is publicly traded company for more then 7 years since IPO on 19 Apr 2018.
-
What is Surface Oncology's official website?
The official website for Surface Oncology is surfaceoncology.com.
-
Where are Surface Oncology's headquarters?
Surface Oncology is headquartered at 50 Hampshire Street, Cambridge, MA.
-
How can i contact Surface Oncology?
Surface Oncology's mailing address is 50 Hampshire Street, Cambridge, MA and company can be reached via phone at +61 77144096.
Surface Oncology company profile:
Surface Oncology, Inc.
surfaceoncology.comExchange:
NASDAQ
Full time employees:
35
Industry:
Biotechnology
Sector:
Healthcare
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
50 Hampshire Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001718108
ISIN: US86877M2098
CUSIP: 86877M209
